Polyploid giant cancer cell characterization: New frontiers in predicting response to chemotherapy in breast cancer.
Polyploid giant cancer cell characterization: New frontiers in predicting response to chemotherapy in breast cancer.
复制标题
DOI：
10.1016/j.semcancer.2021.03.017
复制
发表时间：
2022-06
影响因子：
14.5
通讯作者：
Aneja R
中科院分区：
文献类型：
--
作者：
Saini G;Joshi S;Garlapati C;Li H;Kong J;Krishnamurthy J;Reid MD;Aneja R
虽然多倍体细胞在近两个世纪前就被首次描述，但它们的增殖能力直到最近才被证明。越来越明显的是，肿瘤细胞的一个亚群，多倍体巨型癌细胞(PGCCs)，在乳腺癌(BC)和其他癌症类型的病理生理学中发挥着关键作用。在BC，PGCCs可以在治疗诱导的应激反应中产生。他们的后代具有癌症干细胞(CSC)特性，并能在肿瘤中重新繁殖。PGCCs通过调节肿瘤微环境，促进BC进展、化疗耐药、转移和复发，最终影响BC患者的生存。鉴于它们的促肿瘤作用，PGCCs已被认为具有预测BC患者治疗反应和患者预后的能力。传统上，DNA细胞术是用来检测PGCC的。该领域将进一步受益于开发使用强大的PGCC生物标记物准确检测PGCC及其后代的方法。在这篇综述中，我们介绍了关于结直肠癌临床相关性的知识现状。我们还建议使用人工智能辅助图像分析管道来识别PGCC，并绘制它们与其他TME组件的相互作用图，从而促进临床应用PGCC作为生物标志物来预测BC患者的治疗反应和生存结果。最后，我们总结了靶向PGCCs以预防化疗耐药和改善BC患者临床结局的努力。
Although polyploid cells were first described nearly two centuries ago, their ability to proliferate has only recently been demonstrated. It also becomes increasingly evident that a subset of tumor cells, polyploid giant cancer cells (PGCCs), play a critical role in the pathophysiology of breast cancer (BC), among other cancer types. In BC, PGCCs can arise in response to therapy-induced stress. Their progeny possess cancer stem cell (CSC) properties and can repopulate the tumor. By modulating the tumor microenvironment (TME), PGCCs promote BC progression, chemoresistance, metastasis, and relapse and ultimately impact the survival of BC patients. Given their pro- tumorigenic roles, PGCCs have been proposed to possess the ability to predict treatment response and patient prognosis in BC. Traditionally, DNA cytometry has been used to detect PGCCs.. The field will further derive benefit from the development of approaches to accurately detect PGCCs and their progeny using robust PGCC biomarkers. In this review, we present the current state of knowledge about the clinical relevance of PGCCs in BC. We also propose to use an artificial intelligence-assisted image analysis pipeline to identify PGCC and map their interactions with other TME components, thereby facilitating the clinical implementation of PGCCs as biomarkers to predict treatment response and survival outcomes in BC patients. Finally, we summarize efforts to therapeutically target PGCCs to prevent chemoresistance and improve clinical outcomes in patients with BC.
登录
查看更多内容
影响因子：
--
作者：
Donovan, Prudence;Cato, Kathleen;Harding, Angus
通讯作者：
Harding, Angus
影响因子：
5.1
作者：
Al-Milaji, Zahraa;Ersoy, Ilker;Bunyak, Filiz
通讯作者：
Bunyak, Filiz
影响因子：
4.7
作者：
Coward J;Harding A
通讯作者：
Harding A
Twist2通过促进上皮-间质转化和癌症干细胞样细胞自我更新促进乳腺癌进展
影响因子：
8
作者：
Fang, X.;Cai, Y.;Ouyang, G.
通讯作者：
Ouyang, G.
影响因子：
1.7
作者：
BAISCH, H;GOHDE, W;LINDEN, WA
通讯作者：
LINDEN, WA